Radio and PodcastRadio and PodcastLive Radio & Podcasts
Tazemetostat Withdrawl and RECITE artwork
Science & Medicine

Tazemetostat Withdrawl and RECITE

OncoPharm by OncoPharmPod

Mar 19, 202600:14:47Science & Medicine

Tazemetostat is withdrawn from the market due to a risk of secondary malignancies. RECITE asks if romiplostim improves platelet counts for patients on oxaliplatin-based regimens with thrombocytopenia. Spoiler - yes it do...

About This Episode

Tazemetostat Withdrawl and RECITE is an episode from OncoPharm by OncoPharmPod. Tazemetostat is withdrawn from the market due to a risk of secondary malignancies. RECITE asks if romiplostim improves platelet counts for patients on oxaliplat...

Podcast

This episode belongs to OncoPharm.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Mar 19, 2026, 00:14:47 long, audio available.

Related Episodes

Continue listening to more episodes from OncoPharm.

Asco '26

Jun 11, 2026 - 00:25:38

ASCO 2026 is a wrap, and we needed an extra week to digest it all! Here the review list: 1. RASolute 302...

Pivekimab sunirine

May 28, 2026 - 00:13:49

Pivekimab sunirine, a novel CD-123 antibody drug conjugate is approved for Blastic Plasmacytoid Dendritic...

IMHOTEP, PJP, and more

May 14, 2026 - 00:09:59

This week's pod has lots of updates! IMHOTEP: Pre-operative doses of pembrolizumab lead to significant pC...

Vepdegestrant

May 7, 2026 - 00:11:35

The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated br...

Targets Trop 2

Apr 30, 2026 - 00:12:41

This is our 1st in a series of podcasts/videos to role out once or twice a year on therapeutic targets in...

Promising Pancreatic Cancer Data

Apr 23, 2026 - 00:13:56

This week we highlight some promising clinical research in the pancreatic cancer space. Daraxonrasib has...